Erratum to: The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries (Adv Ther, 10.1007/s12325-017-0522-y)

L. Gulácsi, Valentin Brodszky, Petra Baji, Fanni Rencz, Márta Péntek

Research output: Contribution to journalComment/debate

1 Citation (Scopus)

Abstract

The authors of this manuscript have noticed a mistake since publication of their manuscript. In the original publication, the ‘Total RTX consumption per patient (mg)’ in Table 1, was incorrectly published as 1814.00. The correct value of ‘Total RTX consumption per patient (mg)’ should read as 11,814.00. Open Access. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/ by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Original languageEnglish
Number of pages1
JournalAdvances in Therapy
Volume34
Issue number5
DOIs
Publication statusPublished - May 1 2017

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Erratum to: The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries (Adv Ther, 10.1007/s12325-017-0522-y)'. Together they form a unique fingerprint.

  • Cite this